SNMMI supports radiopharmaceutical pass-through legislation
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is urging the U.S. Congress to pass legislation that would keep the pass-through status for diagnostic radiopharmaceuticals under Medicare reimbursement.
In January, the U.S. Centers for Medicare and Medicaid Services (CMS) revoked pass-through status for a handful of radiopharmaceuticals but was reversed by legislation signed in March. That legislation re-established pass-through status effective Oct. 1 of this year through Dec. 31, 2019.
Sponsored by Reps. George Holding (R-North Carolina) and co-sponsored by Seth Mouton (D-Massachusetts), H.R. 6948 is being reviewed by the House Energy and Commerce and the Ways and Means Committees, according to a recent SNMMI press release.
The SNMMI is joined by the Medical Imaging Technology Association (MITA) and the Council on Radionuclides and Radiopharmaceuticals (CORAR) to support passage of the bill.
A recent graduate from Dominican University (IL) with a bachelor’s in journalism, Melissa joined TriMed’s Chicago team in 2017 covering all aspects of health imaging. She’s a fan of singing and playing guitar, elephants, a good cup of tea, and her golden retriever Cooper.